EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MeiraGTx Holdings's enterprise value is $496.82 Mil.
MeiraGTx Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-121.84 Mil. Therefore, MeiraGTx Holdings's EV-to-EBITDA for today is -4.08.
The historical rank and industry rank for MeiraGTx Holdings's EV-to-EBITDA or its related term are showing as below:
MGTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.12 Med: -5.68 Max: -1.85
Current: -4.08
During the past 9 years, the highest EV-to-EBITDA of MeiraGTx Holdings was -1.85. The lowest was -13.12. And the median was -5.68.
MGTX's EV-to-EBITDA is ranked worse than 100% of 497
companies
in the Biotechnology industry
Industry Median: 7.85
vs MGTX: -4.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
MeiraGTx Holdings EV-to-EBITDA Historical Data
The historical data trend for MeiraGTx Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MeiraGTx Holdings's EV-to-EBITDA
For the Biotechnology subindustry, MeiraGTx Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's EV-to-EBITDA falls into.
MeiraGTx Holdings's current Enterprise Value is $496.82 Mil.
MeiraGTx Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-121.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MeiraGTx Holdings's PE Ratio (TTM) for today is calculated as:
MeiraGTx Holdings's share price for today is $5.87.
MeiraGTx Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of MeiraGTx Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MGTX has been successfully added to your 